Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Classical hematology 1

Conditions

Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Breast Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Lung Neoplasms 1Leukemia, Myelomonocytic, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Congenital Abnormalities 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms, Male 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cytarabine 72Etoposide 29Daunorubicin 25Filgrastim 24Idarubicin 22Mitoxantrone 21Busulfan 21Peripheral Blood Stem Cell Transplantation 20Cyclophosphamide 20fludarabine phosphate 18Gemtuzumab 13Antilymphocyte Serum 12tipifarnib 11Radiotherapy 11Gene Expression Profiling 10Flow Cytometry 10Cyclosporine 10Clofarabine 10sargramostim 9Methotrexate 9Azacitidine 8aldesleukin 6Vorinostat 6Topotecan 6Tacrolimus 6valspodar 5alvocidib 5Whole-Body Irradiation 5Granulocyte Colony-Stimulating Factor 5Cord Blood Stem Cell Transplantation 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Leukemia, Megakaryoblastic, Acute × Drug Screening Assays, Antitumor × Clear all
NCT01872819 2018-07-11

Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay

University of Washington

Phase NA Completed
16 enrolled 9 charts
Classical hematologyMyeloidOther hematologic neoplasm

Congenital Abnormalities, Anemia, Refractory, with Excess of Blasts, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡